Can blood tests spot Alzheimer's risk in all ethnicities? barcelona study aims to find out
NCT ID NCT07521722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will check if levels of Alzheimer's-related substances in the blood differ among the main ethnic groups living in central Barcelona. Researchers will also look at how age, income, education, and health conditions affect these levels. The goal is to identify barriers to using these blood tests in primary care and ensure everyone has fair access to early Alzheimer's prevention. The study will involve 250 cognitively healthy adults aged 50 to 75.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help ensure that Alzheimer's blood tests work equally well for all ethnic groups, leading to fairer early detection and prevention strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any drug or therapy, so it cannot directly improve health. Results may show differences but not explain why or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will enroll 250 cognitively unimpaired adults aged 50-75 years, recruited from the patient registry of the Primary Care Team Raval Sud (EAP Raval Sud) in Barcelona, Spain. This primary care center is embedded in the Raval neighborhood of the Ciutat Vella district, one of the most ethnically diverse areas of Barcelona, characterized by a high proportion of foreign-born residents (over 63%)
- Ages
-
50 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
INCLUSION CRITERIA * Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent * Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context. * Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling. * Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant. EXCLUSION CRITERIA * Cognitive decline defined by CDR\>0. * Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life * Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study. * Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc). * Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy). * Parkinson's disease, epilepsy under treatment and with frequent seizures (\> 1/month) in the last year, multiple sclerosis or other neurodegenerative diseases.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
BarcelonaBeta Brain Research Center - EAP Raval Sud
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can group wellness classes improve life after brain injury or dementia?
- Can a short talk with your doctor lower dementia risk?
- Can VR help people with dementia master daily tasks?
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- A simple gel meets the Mouth's microscopic zoo